BCAX - CIK 0002023658
The table below shows Bicara Therapeutics Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 |
|---|---|---|---|---|---|
| Cash & equivalents | $323.46M | $171.67M | $436.61M | $462.06M | $520.76M |
| Short-term investments | $216.29M | $118.49M | - | - | - |
| Receivables | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Total current assets | $544.91M | $297.37M | $444.39M | $470.75M | $521.51M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Property, plant & equipment | $346.00K | $135.00K | $117.00K | $136.00K | $130.00K |
| Goodwill | - | - | - | - | - |
| Total assets | $553.60M | $424.69M | $453.59M | $478.08M | $524.17M |
| Accounts payable | - | - | - | - | - |
| Total current liabilities | $39.34M | $21.03M | $17.23M | $19.12M | $14.48M |
| Long-term debt | - | - | - | - | - |
| Total liabilities | $39.64M | $21.91M | $18.39M | $19.12M | $14.62M |
| Retained earnings | -$415.18M | -$321.58M | -$285.25M | -$257.86M | -$200.06M |
| Total equity | $513.96M | $402.78M | $435.20M | $458.96M | $509.56M |